Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Gynecologic 4Sarcoma 3Gastrointestinal 3Other hematologic neoplasm 2Genitourinary 2Breast 2Other solid neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 65Nivolumab 58Magnetic Resonance Spectroscopy 53enzalutamide 39Abiraterone Acetate 37Radiosurgery 36Gemcitabine 35Specimen Handling 32Radiotherapy 32Ipilimumab 32Androgen Antagonists 32Prednisone 31apalutamide 28Cisplatin 28Docetaxel 27Leuprolide 26atezolizumab 25Carboplatin 25durvalumab 23cabozantinib 23darolutamide 20acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 19olaparib 18Goserelin 17Radiation 16Gonadotropin-Releasing Hormone 16Biopsy 16gallium 68 PSMA-11 15Pluvicto 15avelumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × ceralasertib × Genitourinary × Clear all
NCT03682289 2026-04-23

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

University of California, San Francisco

Phase 2 Active not recruiting
83 enrolled
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT03787680 2026-03-23

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

University of Michigan Rogel Cancer Center

Phase 2 Active not recruiting
49 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡